ACBM Arco Biomedical Company Ltd (CE)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 7, 2020, the Company’s sole director adopted the 2020 Long-Term Incentive Plan, pursuant to which a maximum of 12,000,000 shares of common stock may be issued pursuant to restricted stock grants, incentive stock options, non-qualified stock options and other equity-based incentives may be granted.  Awards under the plan may be issued to employees, directors of the Company or its affiliates or consultants.  As of the date of this report, no options, stock grants or other equity-based incentives have been granted pursuant to the plan. The plan is to be administered by a committee or, in the absence of a committee, by the board of directors.  Since the Company has one director, Pao-Chi Chu, Mr. Chu, as the sole director, will administer the plan.

On August 8, 2020, pursuant to a written consent of stockholders, executed by Pao-Chi Chu, the holder of 30,000,000 shares of common stock, representing 62.8% of the Company’s outstanding common stock, approved the 2020 Long-Term Incentive Plan and voted for the election of Pao-Chi Chu as the sole director of the Corporation, to serve in such capacity until the 2021 annual meeting of stockholders and until his successor is elected and qualified.

Mr. Chu, age 66, has been the Company’s chief executive officer, chief financial officer, president, secretary and a director since January 30, 2017. Mr. Chu has served as the chairman of Mucho Biotech Co., Ltd., Mucho Furich Co., Ltd., and Mucho Biomedical Co., Ltd., companies engaged in applications of cordyceps since 2006 and which are controlled by Mr. Chu. Mr. Chu has more than ten years of experience in the biotech industry with a focus on initiating the integration of cordyceps technology development, which includes cordyceps strains management, cordyceps cultivation, food processing and health products development. Mr. Chu is a graduate of Fu Jen Catholic University in Taipei, Taiwan.